David Lebovitz
Stock Analyst at Citigroup
(3.22)
# 1,020
Out of 4,876 analysts
95
Total ratings
65.62%
Success rate
7.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $55.17 | +41.38% | 4 | May 2, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $338 → $351 | $322.83 | +8.73% | 31 | Mar 21, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $300.75 | +55.94% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $29.96 | +147.00% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $51.07 | -25.59% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $49.84 | -65.89% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $128.11 | -28.19% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $62.73 | -13.92% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $39.80 | -12.06% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.19 | +1,328.57% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $0.73 | +1,404.99% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $172.14 | +15.60% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $4.33 | +10,985.45% | 2 | Nov 3, 2020 |
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $55.17
Upside: +41.38%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $338 → $351
Current: $322.83
Upside: +8.73%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $300.75
Upside: +55.94%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $29.96
Upside: +147.00%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $51.07
Upside: -25.59%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $49.84
Upside: -65.89%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $128.11
Upside: -28.19%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $62.73
Upside: -13.92%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $39.80
Upside: -12.06%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.19
Upside: +1,328.57%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $0.73
Upside: +1,404.99%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $172.14
Upside: +15.60%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $4.33
Upside: +10,985.45%